



FY2023 RESULTS

March 28, 2024

HBM HOLDINGS-B
2142-HK





Disclaimer

This presentation has been prepared by HBM Holdings Limited (the “Company”) solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

This document has been prepared by the Company solely for use at this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of its affiliates, directors, officers, advisors or representatives will be liable (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising from or in connection with this presentation.

This presentation contains statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this presentation, except as required by law.

Agenda

HARBOUR
BIOMED

01

HBM Holdings:
Value Creation through Globalization and Sustainable Growth

Jingsong Wang MD PhD

02

Harbour Therapeutics:
Efficient and Synergized Pipeline Advancement

Xiaolu Tao PhD / Yiping Rong PhD

03

Nona Biosciences:
Strong Growth Empowered by Innovation



Yun He PhD

04

Partnerships:
Innovative Platform Endorsed by Global Leading Players

Youchen Chen MBA

05

Financial Highlights:
Sizable and Remarkable Net Profits Achieved

Lisa Tong EMBA

06


Outlook:
**Advance Technology Innovation and
Continue to Focus on Unmet Medical Needs**

Jingsong Wang MD PhD

HBM Holdings: Value Creation through Globalization and Sustainable Growth

Dr. Jingsong Wang

Founder, Chairman of the Board and
Chief Executive Officer



HBM Holdings: Value Creation through Globalization and Sustainable Growth



Note: USD/RMB = 7.1

1. As per FY23 Management accounts; 2. If including the upfront payment in relation to HBM9033 received in January 2024

Harbour Therapeutics: Efficient and Synergized Pipeline Advancement



Dr. Xiaolu Tao

President of Harbour Therapeutics



Dr. Yiping Rong

Executive Director,
Chief Scientific Officer

Harbour Therapeutics – FY23 Business Highlights


Clinical Stage Assets



- ✓ Batoclimab (HBM9161), gMG: 🇨🇳
 - Completion of phase III clinical trial
 - Publication of Ph III study results in top medical journal *JAMA Neurology*
- ✓ 2 clinical data readouts for Porustobart (HBM4003) 🇨🇳
- ✓ 2 clinical milestones
 - Completion of HBM9378 Ph I study 🇨🇳
 - Conduction of HBM1020 Ph I study 🇺🇸
- ✓ 5 IND approvals from FDA 🇺🇸
 - HBM1020, HBM1007, HBM1022, HBM9027, HBM9033

Collaboration Assets



- ✓ 1 regional license-out to accelerate global R&D

- ✓ 5 preclinical collaboration assets/licenses advanced to clinical stage
 - AstraZeneca: HBM7022/AZD5863
 - Hualan Bio: HBM7020, HBM7015, HBM1029
 - NK CellTech: NK-010

AstraZeneca

華蘭生物
HUALAN BIO



Preclinical Stage Assets




- ✓ Advancing global pipeline of highly differentiated next-gen therapeutics
- ✓ Strategically promote the R&D of **MULTIPLE** immune cell engager bispecifics



Direct Killing



Stimulate Immune Cells








Overcome Immune Suppression

Focus on China with Global Perspective
Rapidly Advance Next-Generation of Innovative Immunotherapy in Oncology



Highly Innovative and Differentiated Global Pipeline


Project	Target	Indication	Commercial Rights	Status						
				Discovery	Pre-Clinical	IND	Phase I	Phase II	Phase III	BLA
Batoclimab HBM9161	FcRn	Myasthenia Gravis	Greater China Rights Out-licensed ¹	Phase III						
Porustobart HBM4003	CTLA-4 ²	Solid Tumors ^a	Global	Monotherapy Ph 1b/2						
		Solid Tumors ^b		Combo with PD-1 Ph 1b/2						
		Solid Tumors ^c		Combo with PD-1/PD-1+Chemo Ph 1						
HBM7008	B7H4×4-1BB	Solid Tumors	Ex-U.S. ³	Ph 1 						
HBM9378	TSLP	Asthma	Global	Ph 1 						
HBM1020	B7H7/HLA2	Solid Tumors	Global	Ph 1						
HBM7022	CLDN18.2×CD3	Solid Tumors	Global Out-license	Ph 1/2 						
HBM1007	CD73	Solid Tumors	Global	US IND clearance in January 2023						
HBM1022	CCR8	Solid Tumors	Global	US IND clearance in February 2023						
HBM9033	MSLN ADC	Solid Tumors	Global Out-license	US IND clearance in August 2023 						
HBM9027	PD-L1×CD40	Solid Tumors	Global	US IND clearance in January 2024						
HBM7004	B7H4×CD3	Solid Tumors	Global							
HBM1047	CD200R1	Solid Tumors	Global							
HBM9014	LIFR	Solid Tumors	Global							

Batoclimab (HBM9161) Demonstrates Remarkable Therapeutic Benefits in gMG Patients




Highlights

- First and only innovative drug targeting FcRn that has completed phase I,II and III clinical trials in China
- First innovative drug for gMG that has been granted breakthrough therapy designation by CDE
- First and only innovative drug that has achieved outstanding phase III positive results in China gMG patients
- First subcutaneous injection production for FcRn target in China, providing better convenience for gMG patients



Efficacy: Consistency in the MG-ADL improvement, effect onset and duration for each treatment circle



Note: Sustained improvement was defined as a ≥ 3 -point reduction from baseline MG-ADL score from day 1 to day 64 that persisted for 4 weeks. The analysis of sustained improvement rates only included subjects who completed at least 6 visits between weeks 2 and 9 within each cycle

■ Ph III Study Results of Batoclimab (HBM9161) Published in Top ■ Medical Journal – JAMA Neurology



JAMA Neurology (March 2024)

- Clinical Data demonstrate the **efficacy and safety** of Batoclimab in adult patients with generalized MG
- The MG-ADL score diverged between antibody-positive patient group and placebo group as early as week 2, suggesting Batoclimab is able to **take effect quickly** and **improve symptoms**
- The rate of sustained MG-ADL improvement in the first cycle in antibody-positive patients was 31.3% in placebo group vs 58.2% in the Batoclimab group, suggesting Batoclimab can **significantly improve patient symptoms** with **sustainable therapeutic effects**
- In the 1st treatment cycle, the proportion of patients in antibody-positive patient group reaching the mildest symptom manifestations was **25.4%**, much higher than the 4.7% in placebo group.

Research

JAMA Neurology | **Original Investigation**

Batoclimab vs Placebo for Generalized Myasthenia Gravis A Randomized Clinical Trial

Chong Yan, MD; Yaoxian Yue, MD; Yuzhou Guan, MD; Bitao Bu, MD; Qing Ke, MD; Ruisheng Duan, MD; Hui Deng, MD; Qun Xue, MD; Haishan Jiang, MD; Fei Xiao, MD; Huan Yang, MD; Ting Chang, MD; Zhangyu Zou, MD; Haifeng Li, MD; Song Tan, MD; Haibing Xiao, MD; Hongyu Zhou, MD; Hua Zhang, MD; Qiang Meng, MD; Wenyu Li, MD; Wei Li, MD; Junhong Guo, MD; Yali Zhang, MD; Zunbo Li, MD; Jianglong Tu, MD; Jianquan Shi, MD; Wei Li, MD; Michael Lee, PhD; Yu Chen, MD; Xiaolu Tao, PhD; Shuai Zhao, MS; Ping Li, MS; Chongbo Zhao, MD; for the Batoclimab Study Team




Porustobart (HBM4003)

Clinical Benefit and Market Opportunities in Various Tumors

Robust efficacy observed for HBM4003 + Toripalimab in PD-1 naïve melanoma cohort

Best Overall Response by RECIST 1.1, N (%)


Pts with tumor assessments	15 (100%)
ORR (CR + PR)	5 (33.3%)
DCR (CR + PR +SD)	11 (73.3%)
Tumor reduction	9 (60.0%)



HBM4003 + Toripalimab elicited significant efficacy improvement in high-grade NENs patients

Best Overall Response by RECIST 1.1, N (%)

Pts with tumor assessments	19 (100%)
ORR (CR + PR)	7 (36.8%)
DCR (CR + PR +SD)	11 (57.9%)
Tumor reduction	12 (70.6%)




Excellent therapeutic potential observed for HBM4003 in patients with HCC

- HBM4003 monotherapy has demonstrated **preliminary efficacy** in late-stage liver cancer patients resistant to PD-1 treatment
 - ✓ 0.45mg/kg Q3W dose group: 1CR, 1PR
- HBM4003 in combo with Toripalimab has shown **promising therapeutic efficacy** in patients with HCC who have been treated with TKI

Best Overall Response by RECIST 1.1, N (%)


Best Overall Response, n(%)	RECIST 1.1	mRECIST
Pts with tumor assessments	15 (100%)	15 (100%)
ORR (CR + PR)	6 (40.0%)	6 (40.0%)
DCR (CR + PR +SD)	11 (73.3%)	10 (66.7%)
Tumor reduction	10 (66.7%)	10 (66.7%)

Minimum Percent Change in Target Lesion (%)





Porustobart (HBM4003) – Pivotal Trial Preparations



HBM4003 combination therapy with anti-PD-1

HBM1020 (B7H7/HHLA2)

An Alternative Immune Escape Mechanism Beyond PD-L1




Highlights

- T cell and NK cell activation activity and excellent in vivo efficacy in humanized tumor models
- Widely Expressed in Various Solid Tumors & Reciprocal to the Expression of PD-L1
- Huge potential to treat PD-L1 negative or anti-PD1/PD-L1 refractory cancer patients
- HBM1020 is the first and only mAb entering clinical development worldwide
- **Ph1 ongoing - multiple patients dosed in collaboration with top-tier US cancer centers**



MOA



NCT05824663 Indicative Timeline






Building The Technical Foundations on Immune Cell Engager Bispecifics

Partnerships based on Immune Cell Engager Bispecifics



*HBICE targeting
four types of
immune cells*



HBM9027 (PD-L1xCD40)


Innovative Bispecific Antibody Activating APC/T Cells




Highlights

- Synergistically activating both myeloid/DC cells and T cells is critical for some solid tumor therapy considering the most abundant myeloid cell population in TME
- Well maintained α PD-L1 arm and α CD40 arm function activity with robust developability using fully human symmetrical HBICE® format
- Encouraging in vivo efficacy superior to Tecentriq and safety profile is much better than Selicrelumab
- **Obtained US IND approval in January 2024**

Molecule Design and MOA



Strong Anti-tumor Activity in hPD-1/hCD40 DKI Mice



■ HBM7004 (B7H4xCD3)

■ Unique “2+1” Asymmetric HBICE® Using Novel TAA and Safer Anti-CD3 Arm




Highlights

- HBICE® technology grants asymmetric structure but less light chain mispairings
- TAA is mainly expressed in low PD-L1 tumors, particularly in gynecological cancers and squamous cell lung cancer
- Potentially combine with PD1 therapy or in-house HBM7008 to overcome T cell engager challenges in solid tumor


Molecule Design and MOA

Optimized anti-CD3 arm, ~200-300nM


Strong bivalent binding to B7H4



Silenced Fc



Strong Anti-tumor Activity in Mouse Tumor Model



Nona Biosciences: **Strong Growth Empowered** **by Innovation**

Dr. Yun He

Chief Technology Officer, Nona Biosciences





Nona Biosciences Empowers Global Therapeutic Innovation



Nona:

Roman Goddess
Who Enables
Others to Succeed

Our Mission

Leveraging industrial leading technology platforms, Nona Biosciences is committed to provide integrated discovery solutions for biotech and pharmaceutical companies from **Idea to IND (I to I)**

We value our promise, we embrace diversity

Leading Innovative Technology Platform

- The world's leading **fully human antibody platform**
- The **ONLY** open platform fully-protected by global IP
- Fully validation by **~20 projects in clinical stage**
- Successful application in GCT, ADC, AI and other fields

Decades of Experience with MNC Endorsement

- Management experience from **top MNCs**
- Strong scientific background from **top academics and industry**
- Rich academic resources and MNC endorsement
- **70+** scientists with ample research and development experience in innovative medicine

Extensive Global Collaborations

moderna

Dragonfly

KELUN-BIOTECH
科伦博泰

BeiGene

Innovent
信达生物制药

DualityBio
映恩生物

>50

partners including MNC, biotech and academic institutions, forming a large innovative network

Nona's Technology Platform Contributes to the Rapid Business Growth Achieved in FY23

Platform-based Research Services

50+
partners
30+
collaborations
in progress

19+
projects entered
into clinical
stage




Technology Licensing

> US\$60m revenue

- ✓ Antibody depot is set up after 8 years of preparation
- ✓ Partnerships with top biotech / biopharmas



Protein
Engineering



Conjugation
Technology



Delivery
Technology



Cell Therapy
Technology




Focusing on 4 application areas.....

FY23 Witnesses the Commercialization of Nona with Sizable Profits



Nona's Unique Growth Model Based on Platform Technology






Harbour Mice[®] - New Generation of Fully Human Antibody Platforms

Harbour Mice[®] Fully Human Antibody Transgenic Mice


H2L2



HCAb



- ✓ Human
- ✓ Natural
- ✓ Optimized
- ✓ Validated






Extend Antibody Discovery Platform to Integrated ADC Discovery Platform



H2L2




HCAb




BsAb

Clinically validated fully human antibody platform


Attribute	Analytical Methods
DAR	HIC
	UV
	mass spec
	RP-HPLC
Purity	SEC (HMW & LMW species)
	HIC (DAR0 content)
Residual free drugs	RP-HPLC (DAR0 content)
	RP-HPLC
Endotoxin	Chromogenic LAL assay
	Recombinant Factor C assay



Comprehensive physicochemical characterization of ADC molecules




Efficacy studies in various tumor models; PK studies; Preliminary toxicities.



Conjugate Unite	Linker	Payload
 Cys-based Mal-based Non-Mal-based Lys-based	Commercialized Linkers Cleavable vc-PABC GGFG Uncleavable hydrazide disulfide PEG-link MCC β-galactoside	Classic Payloads MMAE/MMAF DM1-4 Eribulin Dxd/Exatecan SN38
	Novel Linkers Tuning cleavage efficiency/MoA Recognized by different peptidase Tuning hydrophobicity PEG in side chain PEG in backbone Tuning drug loading capacity	Novel Payloads Other Chemo drugs Immunomodulators CPT derivatives Pacitaxel S100 Agonist

Extensive experience and a variety of established bioconjugation technologies



Full range in vitro evaluation

Explore Frontiers in ADC Field

Collaborate with global ADC experts to build ADC ecosystem

Unveil the advantages of bispecific / biparatopic ADC


Application of HCAb in XDC for Diagnosis & Therapy

DualityBio
映恩生物

LCB
LegoChemBio


宜联生物
MediLink Therapeutics

MYTHIC
THERAPEUTICS



bsAb showed stronger internalization

Radiolabeled anti-MSLN HCAb can quickly penetrate into tumors





H2L2-ADC to MSLN

- ✓ fully human antibody with unique binding epitope
- ✓ Tumor specific cleavable linker with improved stability
- ✓ Superior in vivo potency and promising safety profile


US IND clearance in Aug 2023

HARBOUR
BIOMED





Comprehensive Bispecific Antibody Discovery Workflow to Reinforce Industry-leading HBICE® Platform (HCAb Based Immune Cell Engagers)



HBICE® Platform Has Been Endorsed by Global Partners




HBM7022 (CLDN18.2×CD3)

Unique 2+1 format with better activity and potential larger therapeutic window.



1st Chinese bispecific antibody
to "go global"

HARBOUR
BIOMED



HBM7008 (B7H4×4-1BB)

First-in-class B7H4 ×4-1BB with excellent anti-tumor efficacy and safety profile.




cullinan
ONCOLOGY




Combine mRNA & HBICE® Technologies to Create Next-Gen Therapeutics




RiboHBICE® demonstrates stronger tumor inhibition and longer duration




RiboHBICE® shows longer serum half-life than recombinant protein HBICE®




Longer serum half-life translates to durable cytotoxicity and response




HCAb High-efficiency CAR-T Functional Screening Platform Boosts the Innovation of Cell Therapies




HCAb VH derived CAR-T showed superior cytotoxicity and induce more cytokine release than reference scFv



Cytotoxicity of CAR-T cells




IFN-γ release





Nona's Technology Platform is Open to the Entire Industry




Partnerships: Innovative Platform Endorsed by Global Leading Players

Mr. Youchen Chen

VP, Corporate Development and Investor Relations




Continuous Endorsement from Global Leading Pharma as A Strong Validation of Our Technology Platform



Multimodal and Multidisciplinary Collaborations Extended to Various Top International / Domestic Partners

Collaboration Areas

Types of partners have been increasingly diversified



Financial Highlights: **Sizable Net Profits Achieved** **for the First Time**

Ms. Lisa Tong

Head of Finance






Sizable and Quality Net Profits Achieved for the First Time

Continued Strong Revenue Growth Achieved in FY23

- Revenue achieved **Exponential Growth** from **2021 to 2023**
- Increase in 2023 is mainly attributable to licensing business


(Unit: RMB Billion)



Sizable and Quality Net Profits Realized for FY23

- We achieved **Net Profits** on annual basis for the **FIRST** Time in corporate history, 4 years after IPO


(Unit: RMB Billion)



■ Robust Cash Reserve via Efficient Cost Control and Sizable ■ Net Profits Realized in FY23


Significant Cost Saving from Efficient Management

(Unit: RMB Billion)



Robust Cash Reserve


(Unit: RMB Billion)



Outlook: Advance Technology Innovation and Focus on Unmet Medical Needs

Dr. Jingsong Wang

Founder, Chairman of the Board
and Chief Executive Officer







FY24 Catalysts and Milestones

Harbour Therapeutics



Clinical Stage Assets

- ✓ HBM 9161: BLA re-submission 
- ✓ HBM 4003: initiation of pivotal study, indication expansion 
- ✓ HBM 1020: initial safety data readout 
- ✓ HBM 9378: complete readout of Ph I data 

Collaboration Assets ¹

- ✓ HBM 7008: Ph I data readout
- ✓ HBM 7022: Ph I/II data readout
- ✓ HBM 9033: initiation of Ph I clinical study

Preclinical Assets

- ✓ 1-2 projects to apply for IND

Nona Biosciences



Technology Platform

- ✓ Platform upgrade: HCAb+ / mRNA / CAR-T / AI ...
- ✓ Bispecific / multi-specific antibody
- ✓ Application expansion to PDC, RDC, etc.

Technology Services

- ✓ Expand service network and territories
 - ✓ West Coast, Central US
 - ✓ EU
 - ✓ APAC ...

Technology Licensing

- ✓ Deepen strategic collaboration with leading biotech/pharma and research institutions at technology and asset level
- ✓ Milestone payments achieved

■ Outlook (FY24 and Beyond): ■ Advance Technology Innovation and Focus on Unmet Medical Needs


HARBOUR
BIOMED

Building “HCAb Plus” Ecosystem by Connecting Global Resources

- Multiple **best-in-class** pipelines
- Build antibody pipelines **focusing on tumor immunotherapy** while **diversifying into non-oncology**
- Advance several **first-in-class** innovative drugs to clinical stage
- Become a global leader in **BsAb** while maintaining leading position in mRNA, cell therapy, ADC, etc.
- **Commercialization** through collaborations with partners

Technology
Validation

Innovation



Empowering Global Biotech Ecosystem Through Innovation

- Harbour Mice® continue to disrupt monopoly from overseas innovation
- Explore new modalities including **PDC, RDC, AI**, etc.
- Build “**Nona Innovative Network**” to bridge technology platform with global healthcare resources
- Deepen platform-based strategic collaboration with top MNCs
- Create a multifaceted **ecosystem bridging top-tier industry and academic resources**



HARBOUR
BIOMED

Q&A

Contact us at:

IR@harbourbiomed.com

